Relay Therapeutics President of R&D sold 93,456 shares at $16.94 via pre-arranged 10b5-1 plan; 418,557 shares remain
Donald A Bergstrom, President of R&D, executed a scheduled sale of 93,456 shares at $16.94 on 2026-06-22 under a 10b5-1 trading plan adopted on 2025-10-30, reducing his holdings by 18.3% to 418,557 shares. The sale occurred during a period of significant stock appreciation—the 90-day change shows +78.2% and 30-day change shows +33.3%—though the current price of $18.03 reflects a -4.2% pullback from the 52-week high of $18.83. This transaction is structured and non-discretionary, reflecting a pre-planned divestment rather than a reactive market response. The company remains unprofitable (net income $-73.3M) despite strong revenue growth of +53.4%, creating a backdrop where insider reduction of holdings occurs amid operational losses and elevated stock valuation relative to near-term fundamentals.